Combination of Sotyktu and Enstilar for Plaque Psoriasis

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Enstilar — DRUG
  Add on Enstilar
• Deucravacitinib — DRUG
  6mg QD

Study Details

combination deucravacitinib and enstilar foam

Key Dates

Start date

Dec 6, 2022

Status verified

Mar 2024

Primary completion

Nov 13, 2023

Completion

Nov 13, 2023

Study Design

Enrollment

30 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Deucravacitinib in combination with Enstilar
  deucravacitinib in combination with Enstilar
• Experimental: Deucravacitinib monotherapy
  monotherapy

Primary Outcome Measure

Psoriasis Area and Severity Index 75 at week 12 [ Time Frame: 12 weeks ]

Locations (1)

Find similar trials in East Windsor, NJ

Related Studies

• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
  PHASE4 · Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey